Form 8-K - Current report:
SEC Accession No. 0001193125-26-296398
Filing Date
2026-07-06
Accepted
2026-07-06 17:15:46
Documents
13
Period of Report
2026-06-30
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d136399d8k.htm   iXBRL 8-K 38212
2 EX-99.1 d136399dex991.htm EX-99.1 7125
6 GRAPHIC g136399g99e15.jpg GRAPHIC 3382
  Complete submission text file 0001193125-26-296398.txt   171939

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA nuvb-20260630.xsd EX-101.SCH 3177
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE nuvb-20260630_lab.xml EX-101.LAB 17992
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE nuvb-20260630_pre.xml EX-101.PRE 11259
16 EXTRACTED XBRL INSTANCE DOCUMENT d136399d8k_htm.xml XML 3639
Mailing Address 1500 BROADWAY SUITE 1401 NEW YORK NY 10036
Business Address 1500 BROADWAY SUITE 1401 NEW YORK NY 10036 332-208-6102
Nuvation Bio Inc. (Filer) CIK: 0001811063 (see all company filings)

EIN.: 850862255 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39351 | Film No.: 261156886
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)